Quintiles to incorporate Archimedes’ healthcare simulator
Friday, March 30, 2012
Quintiles and Archimedes, a healthcare modeling organization based in San Francisco, Calif., have formed an agreement to co-promote clinical and commercial solutions for biopharmaceutical companies to help reduce the time and expense associated with developing and marketing novel therapies.
Through this partnership, Quintiles will incorporate Archimedes’ expertise and healthcare modeling technology, the ARCHeS Innovator, into its existing solutions that span the product lifecycle.
“ARCHeS Innovator is a tremendous tool for capturing predictive simulations from real-world research, which is vital to helping biopharma improve efficiency and productivity in the New Health,” said Rick Sax, global head of integrated clinical services, Quintiles. “Turning data into insights will allow customers to make faster, better decisions across the product lifecycle and increase their probability of success.”
Quintiles will promote and provide access to ARCHeS Innovator, a Software as a Service (SAAS) solution that gives users direct access to the Archimedes Model. The Archimedes Model is a full-scale computer simulation model of human physiology, diseases, behaviors, interventions and healthcare systems. Through advanced methods of mathematics, computing and data systems, the model enables users to run clinically realistic virtual trials that drive better decisions in health and economic outcomes research, comparative effectiveness research, clinical trial design and portfolio management.
“Being able to forecast potential outcomes to interventions brings tremendous value for our biopharma customers, who need to increase productivity, shorten timelines and manage risk. Through the simulation and modeling capabilities of Archimedes, we can provide estimates on the impact of interventions, experimental protocols and guidelines on long-term outcomes,” said Michael Ackermann, senior vice president, commercial group, Quintiles.
He added, “This has applications in clinical trial design, product development, commercialization and patient engagement to help our customers increase the probability of their success.”